T-Dxd Role in HER2-Low: Establishing the First Cytotoxic Line After Endocrine Therapy Failure

When endocrine therapy fails in HER2-low disease, is T-DXd the new first cytotoxic line? Drs. Pegram and Iyengar discuss sequencing options, patient preference, and why T-DXd may offer a more effective, personalized bridge after endocrine resistance.